|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0150 CAD | 0.00% |
|
0.00% | -40.00% |
| Market Cap | 918K 655K 573K 528K 487K 63.05M 939K 6.32M 2.48M 30.89M 2.46M 2.41M 106M | P/E 2024 |
-40.5x | P/E 2025 | -5.33x |
|---|---|---|---|---|---|
| Enterprise Value | 1.92M 1.37M 1.2M 1.1M 1.02M 132M 1.96M 13.19M 5.17M 64.49M 5.14M 5.02M 222M | EV / Sales 2024 |
929,496,174x | EV / Sales 2025 | - |
| Free-Float |
53.08% | Yield 2024 * |
-
| Yield 2025 | - |
| 3 months | -25.00% | ||
| 6 months | -40.00% | ||
| Current year | -40.00% |
| 1 month | 0.02 | 0.02 | |
| Current year | 0.02 | 0.02 | |
| 1 year | 0.02 | 0.04 | |
| 3 years | 0.02 | 0.09 | |
| 5 years | 0.02 | 0.2 | |
| 10 years | 0.01 | 0.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
CEO | Chief Executive Officer | 57 | 2018-08-02 |
Mahmoud Aziz
PSD | President | - | 2021-05-20 |
Danny Wayne Lee
DFI | Director of Finance/CFO | - | 2020-12-13 |
| Director | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
BRD | Director/Board Member | 57 | 2018-08-02 |
Jamie Lewin
BRD | Director/Board Member | 76 | 2019-03-10 |
Kevin Bottomley
BRD | Director/Board Member | 44 | 2019-09-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 9/9/25 | Other | Chief Executive Officer | 0 | 0% | ||
| 9/9/25 | Option | Chairman | 1,000,000 | 1.6885% | ||
| 9/9/25 | Option | Chief Executive Officer | 1,000,000 | 1.6885% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | 0.00% | -50.00% | -78.57% | 654K | ||
| -0.90% | -0.31% | +13.62% | +80.12% | 48.56B | ||
| -0.23% | -0.63% | +67.00% | +115.81% | 35.65B | ||
| -0.76% | -1.57% | -3.87% | +37.62% | 11.98B | ||
| -0.88% | -1.32% | +18.04% | +92.11% | 11.95B | ||
| 0.00% | +1.90% | +34.67% | +129.06% | 9.29B | ||
| -0.75% | -0.17% | +18.85% | +36.91% | 6.95B | ||
| +3.37% | -0.96% | +46.11% | -4.38% | 6.79B | ||
| -2.25% | -1.40% | +1.39% | +218.40% | 6.7B | ||
| -9.93% | +5.82% | -22.89% | +16.29% | 6.81B | ||
| Average | -1.23% | +0.51% | +12.29% | +64.34% | 14.47B | |
| Weighted average by Cap. | -0.94% | +0.33% | +26.53% | +86.88% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 0 0 0 0 0 0.28 0 0.03 0.01 0.14 0.01 0.01 0.47 | - |
| Net income | -73.2K -52.17K -45.65K -42.09K -38.81K -5.03M -74.84K -503K -198K -2.46M -196K -192K -8.48M | -335K -239K -209K -193K -178K -23M -343K -2.3M -904K -11.27M -898K -878K -38.8M |
| Net Debt | 804K 573K 502K 462K 426K 55.21M 822K 5.53M 2.17M 27.05M 2.15M 2.11M 93.12M | 999K 712K 623K 575K 530K 68.61M 1.02M 6.87M 2.7M 33.61M 2.68M 2.62M 116M |
Employees
4,000
Sector
Pharmaceuticals
- Stock Market
- Stocks
- GENX Stock
Select your edition
All financial news and data tailored to specific country editions
















